Top 10 Pharmaceutical Breakthroughs Set to Become Blockbusters in 2025

As we look ahead to 2025, the pharmaceutical industry is set for some major shifts, with several top-selling drugs dominating the market. While AbbVie’s Humira continues to be a major player, it is expected to be overtaken by newer drugs with promising market potentials.

Here are the Top 10 Pharmaceutical Breakthroughs poised to lead the way in 2025:

Merck’s Keytruda

Merck’s Keytruda has rapidly become one of the most groundbreaking drugs in the oncology field, and it is poised to secure the #1 position in 2025, with projections reaching an impressive $31 billion in sales. Approved for 30 different indications, Keytruda has already established itself as a leader in immuno-oncology and is on track to become one of the highest-selling pharmaceutical products of all time.

A Decade of Success in Oncology

Since its first approval in 2014, Keytruda has achieved remarkable growth, with annual sales increasing exponentially:

Expanding Reach and Approvals

Keytruda has achieved significant milestones with its approval for 39 indications across 17 tumor types, offering a broad range of treatment options for cancer patients. The drug’s success continues to grow, particularly in earlier stages of disease, where effective intervention can improve patient outcomes.

One of the most notable advancements came in 2023, with Keytruda gaining FDA approval for non-small cell lung cancer (NSCLC) treatments, including the KEYNOTE-091 and KEYNOTE-671 studies, which demonstrated success in event-free survival and overall survival. Keytruda is also making strides internationally, with approval in China in 2024 for combination therapy in resectable stage II, IIIA, or IIIB NSCLC, offering a new treatment option for patients with this challenging condition.

The Road Ahead

Looking ahead, Keytruda’s future is bright as it continues to expand into new indications and markets globally. The oncology drug is not just a current leader but is set to maintain its dominance in the field, contributing significantly to Merck’s growth. However, with the expiration of its patent approaching, Merck faces challenges in replacing Keytruda’s revenue, which could impact its stock price. Despite this, Keytruda’s position as a cancer treatment powerhouse is secure for the time being, and its peak sales in 2025 will set a new benchmark for the pharmaceutical industry.

While Keytruda continues to break sales records, the future of this blockbuster drug may face some challenges. The drug’s patent is set to expire in 2028, creating a significant shift in its market dynamics. As Keytruda becomes more vulnerable to competition, the entry of biosimilars essentially generic versions of the drug could lead to a ~20% drop in sales by 2028, according to consensus forecasts from DataM analysis.

The anticipated loss of patent protection will open the door to biosimilars , which are likely to be more cost-effective alternatives to Keytruda. This influx of competition could potentially reduce Merck’s revenue from Keytruda, but the company is already focused on expanding its pipeline and exploring new markets to mitigate these risks.

What’s Next for Keytruda?

Despite the looming threat of biosimilars, Keytruda’s market dominance remains strong, especially as it continues to expand into new indications and territories. With ~30 FDA-approved indications across 17 tumor types, Keytruda is well-positioned to maintain its leadership in oncology for the next few years.

Merck’s commitment to innovation, including exploring earlier-stage disease treatments and precision therapies, will continue to drive the drug’s success in the short term. However, the eventual competition from biosimilars after 2028 will require Merck to adapt and find new avenues to sustain its growth.

Bristol-Myers Squibb’s Eliquis

DataM Intelligence, a leading market research firm, has provided detailed sales predictions for Eliquis, one of the most prominent blood-thinning medications in the world. With the growing global demand for treatments aimed at preventing strokes and blood clots, DataM’s forecasts are highly anticipated by industry professionals and investors.

According to DataM Intelligence’s predictions, Eliquis is set to generate $18.7 billion in sales by 2025, retaining its position as the second-highest-grossing drug in the market. This projection reflects a continued upward trajectory in sales, with Eliquis consistently outperforming analysts’ estimates. In the third quarter of 2024 alone, the drug’s sales increased by 11%, reaching $3 billion, surpassing the predicted $2.83 billion.

DataM Intelligence has also provided a year-by-year breakdown of Eliquis’ anticipated revenue, showing steady growth from $9.17 billion in 2020 to an expected $12.9 billion in 2024. While the growth will slightly slow down post-2025, with 2026 predicted sales of $10 billion, Eliquis is expected to remain a top performer in the pharmaceutical sector for years to come.

These predictions are based on several factors, including Eliquis’ strong clinical track record, its effectiveness in preventing strokes and blood clots, and the growing global market for anticoagulants. Despite the looming patent expiration in 2026, which may bring competition from generic versions, DataM’s forecast suggests that Eliquis will maintain a significant market share until then.

The patent for Eliquis is set to expire on November 21, 2026, marking a significant milestone in its lifecycle. However, the drug’s protection is extended by a Supplementary Protection Certificate (SPC), which will prolong its exclusivity until the end of 2026.

An SPC is a mechanism used in Europe to compensate for time lost during the drug’s development process, granting additional protection to innovative pharmaceutical products after the basic patent expires. This extension means that Eliquis will remain under patent protection, preventing generic versions from entering the market until at least November 2026. This ensures that Bristol-Myers Squibb retains market exclusivity and the ability to generate substantial revenue from Eliquis before generic competition arises.

Bristol-Myers Squibb’s Revlimid

Revlimid, developed by Bristol-Myers Squibb (formerly Celgene), continues to be a powerhouse in cancer treatment, specifically for multiple myeloma. This oral chemotherapy drug works by enhancing the body’s immune system to target and destroy cancerous cells, providing a crucial treatment option for patients battling this aggressive form of blood cancer.

With its proven effectiveness and safety profile, Revlimid has solidified its position as one of the most widely prescribed therapies for multiple myeloma, leading to its blockbuster status. By 2025, Revlimid is projected to generate an impressive $12.6 billion in sales, maintaining its stronghold in the cancer treatment market.

Despite facing competition from newer therapies and biosimilars, Revlimid remains a cornerstone in the fight against multiple myeloma, offering hope and improved survival rates for many patients. As it continues to perform well in the market, Revlimid exemplifies the critical role of innovative drugs in treating complex and life-threatening diseases like cancer.

Bristol-Myers Squibb’s Opdivo

Opdivo, developed by Bristol-Myers Squibb, is a breakthrough drug in the field of immuno-oncology. As a PD-1 checkpoint inhibitor, Opdivo works by helping the body’s immune system recognize and attack cancer cells. This approach has proven effective in treating various cancers, including melanoma, lung cancer, and kidney cancer, among others.

With its expanding use and solid clinical performance, Opdivo has become a cornerstone in cancer treatment. By 2025, it is expected to generate $11.9 billion in sales, securing its place as one of the top-selling drugs in the world.

The success of Opdivo highlights the growing importance of immunotherapy in cancer care, offering new hope for patients with difficult-to-treat cancers. As research and applications for Opdivo continue to expand, its role in transforming cancer treatment remains critical, making it one of the most important and innovative drugs in the fight against cancer.

Johnson & Johnson’s Imbruvica

Imbruvica, the groundbreaking drug co-developed by Janssen Biotech and Pharmacyclics LLC, has revolutionized the treatment landscape for blood cancers and chronic graft-versus-host disease (cGVHD). With its ability to inhibit Bruton’s tyrosine kinase (BTK), Imbruvica has become a cornerstone in treating conditions such as chronic lymphocytic leukemia (CLL), Waldenström’s macroglobulinemia (WM), and cGVHD. As a once-daily oral medication, it has brought significant benefits to both adult and pediatric patients, improving quality of life and outcomes in previously hard-to-treat diseases.

Imbruvica’s Expanding Role in Oncology and Immunology

Approved by the U.S. FDA in 2013, Imbruvica is currently approved for use in multiple disease indications. Its ability to target and block the BTK protein crucial for the proliferation of abnormal B cells has made it a pivotal therapy in oncology. Additionally, the recent approval of the oral suspension formulation allows greater flexibility for patients, particularly those who face difficulties swallowing pills, further broadening its clinical applications.

With its vast therapeutic reach and proven track record, Imbruvica is now a standard treatment for over 300,000 patients globally, demonstrating its safety and efficacy across more than 50 company-sponsored clinical trials.

Imbruvica’s Patent Expiry and the Impact on the Market

As with all pharmaceutical products, the expiration of a drug’s patent is an important milestone that can impact its market presence and pricing. For Imbruvica, the patent covering its formulation and use for treating cGVHD, particularly in both adult and pediatric patients aged one year and older, is set to expire on October 24, 2034.

The expiration of this patent marks the beginning of a new era in the treatment of blood cancers and cGVHD, as it opens the door for generic manufacturers to develop and market their own versions of the drug. This shift is expected to introduce more affordable treatment options, which could significantly increase patient access, particularly in low-income regions or for those without insurance coverage.

Current Scenario: Balancing Innovation with Accessibility

While the expiration of the patent is still several years away, the pharmaceutical industry is already preparing for the eventual shift toward generics. In the interim, Imbruvica continues to be an essential therapy for patients and clinicians, with ongoing investments in clinical trials to further refine and expand its therapeutic applications.

Moreover, as we approach the patent expiry, it is likely that Janssen Biotech and Pharmacyclics LLC will work to maintain Imbruvica’s market leadership through strategic partnerships, next-generation formulations, and continued innovation in cancer and immune-related therapies.

For patients and healthcare providers, the introduction of generic versions of Imbruvica may offer a more affordable alternative while ensuring that high-quality treatment options remain accessible. However, the period leading up to the patent expiry will remain critical for ensuring that Imbruvica’s efficacy and safety continue to be optimized.

Looking Ahead: A Promising Future for Imbruvica and its Patients

As Imbruvica’s patent expiration nears, the pharmaceutical industry will witness significant changes in the oncology and immunology sectors. This momentous shift will pave the way for increased accessibility, lower drug costs, and potentially broader patient populations receiving treatment. Despite the expiration of the patent, Imbruvica’s continued role in oncology and cGVHD treatment will likely remain pivotal for years to come.

At DataM Intelligence, we continue to monitor the evolving landscape of oncology treatments, with a particular focus on the impact of patent expirations and market dynamics. The future of Imbruvica promises to be one of greater accessibility and continued innovation, which will ultimately benefit both patients and the healthcare system as a whole.

AbbVie’s Humira

AbbVie’s Humira (adalimumab) has long been a powerhouse in the pharmaceutical industry, becoming one of the best-selling drugs in the world. With a diverse range of indications, from rheumatoid arthritis to inflammatory bowel disease, Humira has helped millions of patients manage chronic conditions and improve their quality of life. Despite increasing competition from biosimilars, Humira is still expected to generate over $11 billion in sales by 2025, securing its place among the top-selling drugs globally.

Humira’s Dominance in the Market

Since its approval in 2002, Humira has been a staple in treating autoimmune diseases, particularly due to its ability to target tumor necrosis factor (TNF), a protein involved in inflammation. This biologic has set the bar for other treatments in its class, and its remarkable sales performance topping $20 billion in some years has solidified AbbVie’s position as a leader in the pharmaceutical market.

The broad range of indications, including rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis, has helped Humira maintain its top-tier status, making it a go-to therapy for both patients and healthcare providers.

Biosimilars: The New Competitive Landscape

While Humira’s legacy remains strong, the landscape is shifting. The approval of biosimilars to Humira, which are nearly identical versions of the drug, presents a growing challenge. These biosimilars offer more affordable alternatives, and their market share is gradually increasing, particularly in regions like Europe, where Humira’s exclusivity expired earlier.

In the U.S., AbbVie’s patent protection has kept Humira largely insulated from competition, but that is changing. As Humira’s patent exclusivity period comes to an end, several biosimilars are expected to enter the U.S. market, offering a lower-cost treatment option. This will likely lead to a shift in market share, but Humira’s entrenched position and brand recognition may continue to drive strong sales despite the rise of biosimilars.

Humira’s Resilience in the Face of Competition

Even with the growing presence of biosimilars, Humira is poised to remain a strong contender in the pharmaceutical space. AbbVie has strategically positioned Humira for continued success by expanding its label indications, improving patient access programs, and enhancing its clinical data portfolio. As a result, Humira is likely to continue commanding significant sales, particularly in markets where biosimilar competition is still emerging.

Moreover, AbbVie has already begun transitioning patients to its next-generation product, Rinvoq (upadacitinib), and other pipeline therapies. This transition could help mitigate the impact of biosimilar competition while securing AbbVie’s future growth in immunology.

Looking Forward: The Future of Humira

As the industry shifts toward biosimilars, Humira’s ability to retain its position as one of the world’s highest-grossing drugs is a testament to its impact and the ongoing demand for effective treatments for autoimmune diseases. However, AbbVie will need to navigate the challenges of an increasingly competitive market, and its ability to maintain Humira’s leadership position will depend on strategic efforts in patient access, pricing, and new product innovations.

Gilead’s Biktarvy

Gilead’s Biktarvy continues to be a dominant force in the HIV treatment landscape, with expected sales reaching approximately $11 billion by 2025. As a highly effective, once-daily combination therapy, Biktarvy has become a cornerstone in HIV care, offering patients a potent option for viral suppression with a favorable safety profile. Its strong market position, bolstered by its ability to provide comprehensive treatment in a single pill, ensures that it remains one of the top-selling HIV drugs despite growing competition. As the demand for effective HIV therapies remains high, Biktarvy is set to maintain its place among the top 10 best-selling drugs globally.

Pfizer’s Ibrance

Pfizer’s Ibrance (palbociclib), a CDK4/6 inhibitor, is expected to reach $8.9 billion in sales by 2025, marking significant growth from its current sales of $2.8 billion. As one of the leading treatments for HR-positive, HER2-negative metastatic breast cancer, Ibrance has already transformed the therapeutic landscape, providing patients with an effective option to manage their disease. Recently, the Phase 3 PATINA study demonstrated that combining Ibrance with standard therapies significantly extended progression-free survival by over 15 months in patients with HR+, HER2+ metastatic breast cancer, further expanding its potential. These positive results are likely to bolster Ibrance’s use in combination therapies, reinforcing its strong market trajectory in oncology and helping it maintain its place among top-selling drugs in the coming years.

Johnson & Johnson’s Stelara

Johnson & Johnson’s Stelara (ustekinumab) continues to be a dominant player in the treatment of autoimmune diseases, including psoriasis, Crohn’s disease, and ulcerative colitis. Expected to generate $7.9 billion in sales by 2025, Stelara’s versatility across multiple indications significantly contributes to its continued growth. However, the increasing competition from biosimilars is poised to impact its market share. On December 17, 2024, Celltrion’s Steqeyma (CT-P43) became the seventh biosimilar of Stelara, with a settlement agreement allowing it to enter the U.S. market by March 7, 2025.

Additionally, Amgen’s Wezlana (ustekinumab-auub), the first FDA-approved Stelara biosimilar, will be available starting January 1, 2025, potentially driving further competition in the market. Despite the emergence of biosimilars, Stelara remains a top treatment for autoimmune diseases, with U.S. sales reaching $6.97 billion in 2023. As Stelara faces these new market dynamics, its continued success will rely on its ability to maintain its leadership position while adapting to the growing presence of more affordable alternatives.

Eli Lilly’s Trulicity

Eli Lilly’s Trulicity (dulaglutide), a GLP-1 receptor agonist used in the treatment of type 2 diabetes, is projected to achieve $7.0 billion in peak sales by 2025, solidifying its position as a leading therapy in the diabetes management market.

However, the drug is currently facing a significant supply shortage, with Eli Lilly reporting that the limited availability of Trulicity will persist until June 30, 2025. The shortage is largely due to a surge in demand, exacerbated by the shortage of another popular diabetes drugs or medication , Ozempic (semaglutide). In response, Eli Lilly is working closely with wholesalers and healthcare professionals to manage the situation. While the global demand continues to grow, this ongoing shortage presents challenges for patients, who are advised to consult their doctors if they are unable to access Trulicity. Despite these temporary hurdles, Trulicity remains an essential treatment for diabetes and is expected to continue its strong sales trajectory in the years ahead.